Voyager Acquisition Corp. has announced an update to its previously disclosed Business Combination Agreement with Veraxa Biotech AG, initially announced in April 2025. According to a recent filing, Voyager has entered into a Joinder Agreement with Veraxa, PubCo, and Veraxa Cayman Merger Sub. This agreement integrates PubCo and Merger Sub into the original business combination deal, ensuring they are fully bound by its terms. The Joinder Agreement also outlines the process for transferring assets and liabilities to Merger Sub and the subsequent contribution of Merger Sub shares to PubCo. Additionally, it confirms the ownership structure and management of PubCo and Merger Sub as of the agreement's date.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。